DiabetologiaClinical and Experimental Diabetes and Metabolism© Springer-Verlag 200510.1007/s00125-005-0023-4
Cognitive decline and dementia in diabetes—systematic overview of prospective observational studies
Division of Endocrinology & Metabolism and Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada
Kulynych Center for Memory and Cognition Research, Wake Forest University Health Sciences, Winston-Salem, NC, USA
c/o H.C. Gerstein, Department of Medicine, Room 3V38, 1200 Main Street West, L8N 3Z5 Hamilton, ON, Canada
Received: 17 March 2005Accepted: 21 July 2005Published online: 8 November 2005
We systematically reviewed and summarised prospective data relating diabetes status to changes in cognitive function over time.
Published reports of longitudinal studies that described assessment of cognitive function in people with diabetes were sought. Studies were included if they assessed cognitive function in participants with diabetes at the beginning and at follow-up. Studies were excluded if they had (1) a follow-up period of less than 1 year, (2) a rate of loss to follow-up in excess of 30%, or (3) described selected subgroups. Change in cognitive function was recorded as either the mean change in score and/or the proportion of individuals developing various degrees of change in cognitive function. A pooled estimate was calculated for the latter.
Of 1,165 abstracts and titles initially identified, 25 articles met the inclusion and exclusion criteria. Individuals with diabetes had a 1.2- to 1.5-fold greater change over time in measures of cognitive function than those without diabetes. When assessed by the Mini-Mental State Exam and the Digit Symbol Span tests, a diagnosis of diabetes increased the odds of cognitive decline 1.2-fold (95% CI 1.05–1.4) and 1.7-fold (95% CI 1.3–2.3), respectively . The odds of future dementia increased 1.6-fold (95% CI 1.4–1.8).
Compared to people without diabetes, people with diabetes have a greater rate of decline in cognitive function and a greater risk of cognitive decline. Cognitive dysfunction should therefore be added to the list of chronic complications of diabetes.
KeywordsCognition Cognitive decline Dementia Diabetes Meta-analysis Prospective studies Systematic review
Digit Symbol Substitution
Mini-Mental State Examination
Diabetes is a growing problem throughout the world. The global prevalence of established diabetes was estimated to be 2.8% in 2000 and is projected to be 4.4% by 2030. This prevalence rises with age; for example in the year 2000 12% of people aged 65 to 70 and 15% of people over age 80 were known to have diabetes . Cognitive dysfunction represents another serious problem and is rising in prevalence worldwide, especially among the elderly. For example, in a recent Canadian study the prevalence of dementia (the most severe form of clinically diagnosed cognitive dysfunction) was estimated to be 8% for persons above 65 years of age and 34% for those aged 85 or older .
It is well established that diabetes is an independent risk factor for eye, kidney and neurological diseases as well as for cardiovascular morbidity and mortality. Recent evidence from several epidemiological studies suggests that it is also a risk factor for cognitive dysfunction [3–6]. However, many of these studies were cross-sectional and were thus unable to provide estimates of diabetes as a risk factor for future cognitive dysfunction. Moreover, differences in the analytical approaches and the wide variety of outcome measure used in longitudinal studies have led to varying estimates of the magnitude and importance of the relationship between diabetes and cognitive dysfunction. Indeed, only one  of the review articles that summarised the available data pertaining to this relationship [4, 6–11] provided a quantitative estimate. Such an estimate is of value to both clinicians and researchers. This systematic overview was therefore undertaken to summarise the available prospective studies and to develop an estimate of the magnitude of the risk of incident cognitive dysfunction in people with diabetes.
Materials and methods
Identification of material and inclusion/exclusion criteria
Published reports of longitudinal studies describing assessments of cognitive function in people with diabetes were sought by systematically searching various biomedical databases, talking to experts, and examining the bibliographies of relevant articles. Comprehensive electronic searches for articles were conducted by an experienced librarian and one of the authors (T. Cukierman), using Medline, EMBASE and PsycINFO, to identify studies that prospectively followed a cohort of individuals and that reported on: (1) cognitive function at baseline and at follow-up; and (2) glucose status. The diabetes-related terms and medical subject headings 'diabetes mellitus', 'glucose intolerance', 'glucose blood levels', 'glucose tolerance test', and 'blood glucose' were combined with terms related to cognitive dysfunction, e.g. 'cognition', 'mixed depression and dementia', 'presenile dementia', 'frontotemporal dementia', 'dementia' or 'multiinfarct dementia', 'senile dementia', 'cognitive defect', 'Alzheimer's disease', 'cognition disorders', 'dementia vascular', 'dementia multi infarct', or 'delerium, dementia, amnestic, cognitive disorders', as well as with 'longitudinal'or 'longitudinal studies', 'prospective'or 'meta analysis', and 'randomised controlled trials'.
Studies were included if they: (1) included a cognitive function assessment tool that was either a structured test or a clinical evaluation; (2) described the diabetes or glucose tolerance status of the participants; (3) assessed cognitive function at the beginning and subsequently; (4) provided information relating the diabetes status of the participants to their cognitive function; and (5) were written in English. Studies were excluded if: (1) loss to follow-up exceeded 30% (in studies that reported reasons for loss to follow-up, death was excluded from the estimate); (2) they followed only a subset of individuals with diabetes (e.g. those with neurological conditions or carriers of certain genetic abnormalities); or (3) they reported a follow-up period of less then one year. If studies were reported in more than one publication the most recent article that met the inclusion criteria was analysed; data from the related publications were used when necessary in order to complete the database.
The inclusion and exclusion criteria were applied to all retrieved titles or abstracts of publications, in order to arrive at a final list of eligible papers. Data from the retrieved studies were then abstracted and analysed.
The selected studies were analysed according to previously published methodological criteria  to determine if they reported: (1) a predetermined method for selection of the participants; (2) the definition of diabetes mellitus; (3) the definition of the outcome; (4) use of the same cognitive assessment instrument in the two groups; (5) that data were collected unaware of the diabetes status (blinding); and (6) the degree of loss to follow-up.
The following data were extracted from each study: age; diabetes definition; number of participants with diabetes available for analysis; number of participants without diabetes available for analysis; length of follow-up; the number and types of cognitive assessment tools used; and finally the definition used by the study for the cognitive outcome, i.e. cognitive decline or dementia.
Changes in cognitive test results were recorded as either: the mean change in score (whenever baseline and follow-up scores were available); and/or proportions of individuals developing various categories of cognitive dysfunction or clinical diagnoses such as dementia, vascular dementia or Alzheimer's dementia. The definition of dementia used in each study was accepted for this review.
Common measures of cognitive function
Cognitive function was measured using a variety of simple cognitive tests [9, 13, 14]. The most commonly used of these were: the Mini-Mental State Examination (MMSE)/ Modified Mini-Mental State (3MS) and the Digit Symbol Substitution test (DSS).
The MMSE was devised in 1975 as a tool for assessing cognitive mental status; it is widely used in the clinical setting and in epidemiological research. It has a maximum score of 30 and addresses seven different cognitive domains or functions: orientation to time (5 points), orientation to place (5 points), registration of three words (3 points), attention and calculation (5 points), recall of three words (3 points), language (8 points), visual construction (1 point) . The 3MS is a modified version of the MMSE that maintains the MMSE's basic format while modifying its contents . It contains a few new items, an expanded range of scores (0–100) and a modified scoring procedure. The validity of the MMSE as a screening tool for detecting dementia has been extensively studied ; its ability to detect changes in cognitive function for non-demented individuals has been documented mainly in the elderly .
The DSS measures psychomotor speed with a score ranging from 1 to 133 and requires timed translation of the numbers 1 to 9 into symbols using a key .
For studies reporting continuous data, the mean change in score per year for each cognitive test was calculated by dividing the mean difference in score by the follow-up period (in years). This was done separately for the diabetic and non-diabetic groups. To account for differences in baseline cognitive scores across studies, the mean annual per cent change from baseline was calculated for each score (whenever data were available). The calculated change in score for participants with diabetes was divided by the change in people without diabetes to yield a measure of the effect of diabetes on change in cognitive score. The risks for cognitive decline as measured by the MMSE and the DSS, and for clinically detected dementia in people with diabetes versus those without diabetes were separately pooled and expressed as an overall risk with 95% confidence intervals. The pooled estimates of risk were obtained by combining the separate estimates of inverse variance-weighted log risk ratio estimates from each study. Heterogeneity was assessed using the Q statistic . Review Manager 4.2 for Windows (The Cochrane Collaboration, Oxford, UK) was used for analyses and graphics.
A total of 1,165 abstracts and titles were obtained through the database and bibliography search and reviewed by one of the authors (T. Cukierman). Of these citations, 50 met the inclusion criteria and were fully reviewed and analysed. Of these 50, 25 were excluded from the analysis because they: (1) dealt only with a subset of patients with stroke [21–23]; (2) dealt only with a subset of patients carrying the ApoE4 gene ; (3) had a short follow-up period [25, 26]; (4) had a high per cent of loss to follow-up ; or (5) described the same study and did not include additional relevant data [28–45]. The 25 remaining articles [46–70] comprised data from more than 8,656 people with diabetes, with follow-up periods ranging from 2 to 18 years.
Measures of cognitive function
Cognitive function was assessed using three primary methods: (1) specific cognitive tests (Table 1); (2) a composite endpoint that was either the mean/composite score on two or more tests, or a combination of both clinical assessment and test scores; or (3) clinical assessment alone (for example incident non-specific dementia, vascular dementia or Alzheimer's dementia). Results were reported as either continuous or categorical outcomes.
Cognitive function assessment tools used in studies evaluating the effect of diabetes status
Mini-Mental State Examination (MMSE) or Modified Mini-Mental State Examination (3MS)
Digit Symbol Substitution (DSS)
Trail Making Test (TMTA/B)
Benton Visual Retention Test (BVRT)
Word recall—immediate and delayed (including auditory verbal learning test, Boston memory test, immediate and delayed word recall)
Verbal fluency (including: first letter, word fluency test)
Word list recognition
Digit span (backwards or forwards)
Telephone Interview for Cognitive status (TICS)
Test of Facial Recognition (TRF)
Finger Tapping Test (FTT)
Raven's Progressive Matrices (RPM)
Paced Auditory Serial Addition Test (PASAT)
Immediate and delayed recall of a story (including story A, East Boston story)
Other tests: Boston naming, reading test, digit ordering, alpha span, symbol digit modalities test, number comparison, judgment of line orientation, standard progressive matrices
Studies reporting continuous measures of cognitive decline
Table 2 lists the six studies that reported time-related changes as a continuous variable using either the MMSE or 3MS score in individuals with and without a history of diabetes [49, 51, 52, 54, 65, 69]. Individuals with diabetes experienced a consistently greater decline or lesser improvement than those without diabetes. The ratio of the relative change in score from baseline in people with diabetes compared to those without diabetes ranged from 1.2 to 1.6.
Effect of diabetes status on changes in measurements of cognitive function over time
Annual change from baseline
Annual change from baseline
History (<5 years) glucose
History (>5 years) glucose
Four studies used the DSS as a continuous variable (Table 2) to assess cognitive function and three reported an adverse effect of diabetes on cognitive function over time. Three studies reported a decline ranging from 1.3 to 1.4% per year in people with diabetes. Overall, this decline was up to 1.5 times greater than that in people without diabetes [52, 54, 60]. However, one study reported an improvement in score of 1.2% in people with diabetes; nevertheless this improvement was approximately half of the improvement experienced by the non-diabetic participants .
Three studies reported the effect of diabetes status on changes in a composite score that assessed cognitive function [46, 66, 70]. In these studies, individuals with diabetes had a greater absolute annual decline in score than those without diabetes; however, the differences only achieved statistical significance in one study .
Eight studies reported a variety of other cognitive tests, most of them reporting greater or equal cognitive change for the diabetic participants (Table 1) [46, 49, 51, 58, 63, 66, 69, 70]. Some, but not all of the tests detected a significant difference between the groups with and without diabetes.
Studies reporting categorical measures of cognitive decline
Seventeen studies divided the participants into two groups based on whether or not participants did or did not experience cognitive decline during follow-up. Cognitive decline was defined in a variety of ways that included: (1) a reduction by a particular amount relative to the baseline score; (2) a reduction below a particular threshold score; or (3) progression to clinically diagnosed dementia.
Table 3, and Figs. 1 and 2 list and display results from the six studies that used the MMSE or 3MS [47–51, 54, 62, 69] and the two studies that used the DSS [51, 54] to classify participants into those who did and did not experience cognitive decline. Figs. 1 and 2 also show the pooled estimates of risk. Compared to people without diabetes, people with diabetes were 1.2 times more likely to experience cognitive decline as measured by the MMSE/3MS (95% CI 1.0–1.4) and 1.7 times more likely to experience cognitive decline as measured by the DSS (95% CI 1.3–2.3).
Effect of diabetes status on the risk of cognitive decline (assessed by a single instrument)
Definition (amount of fall)
OR (95% CI)
1.0 (0.5–2.2) f
<20th percentile c
1.2 (0.9–1.6) g,h
M 1.3 (0.6–3.1) F 0.7(0.3–1.7)I
<15th percentile c
Cognitive decline as assessed by the MMSE. Figure shows the risk and 95% confidence intervals of cognitive decline in diabetic (DM) versus non_diabetic (No DM) patients (as measured by the Mini_Mental State Exam), as well as the pooled estimate. Test for heterogeneity: chi square=6.73, df=5 (p=0.24), I 2=25.7%
Cognitive decline as assessed by the DSS. Figure shows the risk and 95% confidence intervals of cognitive decline in diabetic (DM) versus non_diabetic (No DM) patients (as measured by the Digit Symbol Substitution Test), as well as the pooled estimate. Test for heterogeneity: chi square=0.87, df=1 (p=0.35), I 2=0%
Six of these studies used a composite of various other measures of cognitive status to detect cognitive decline (Table 4). This composite was used either alone or in combination with the MMSE, 3MS or DSS [46, 55, 62, 64, 68, 70]. Five of these studies reported that participants with diabetes had a higher risk of developing cognitive decline than those without diabetes; in three of these the lower limit of the 95% confidence interval exceeded 1 (i.e. it was statistically significant).
Effect of diabetes status on the risk of cognitive decline (assessed by a composite score)
Cut-off definition (amount of fall)
Risk (95% CI)
Mean (5 tests)
OR 1.2 (0.97–1.5)c
Composite (5 tests)
OR 0.8 (0.4–1.8)
Clinical dementia rating (CDR)
Increase in rating
RR 2.2 (1.0–4.4)e
Clinical assessment and 3MS test
Vascular cognitive impairmentf
RR 1.8 (1.2–2.5) g
OR 1.8 (1.1–2.8)I
Composite (3 tests)
MCIj without dementia
OR 1.5 (0.6–4.2)k
Finally, six of these 17 studies also reported the odds of decline as measured by a variety of cognitive tests [46, 49, 51, 54, 62, 69]. In these studies, diabetes status predicted an odds ratio for cognitive decline that ranged from 0.7 to 4.4. In some the lower limits of the 95% confidence interval exceeded 1 (i.e. were statistically significant) [6, 46, 51, 54, 69].
Studies reporting the development of future dementia
Eight studies classified participants according to whether or not they developed dementia over time on the basis of a clinical assessment (Table 5, Fig. 3) [56–59, 64–67]. Five of these reported that people with diabetes had a higher risk of all-cause dementia than people without diabetes [56, 58, 64, 65, 67]. Overall, people with diabetes were 1.6 times more likely to develop all-cause dementia than people without diabetes (95% CI 1.4–1.8).
Effect of diabetes status on the risk of future clinically diagnosed dementia
Risk (95% CI)
RR 1.9 (1.3–2.8)a
RR 2.2 (0.97–4.9)c
M: RR 2.3 (1.5–3.3)c F: RR 1.4 (0.9–2.0)c
HR 1.3 (0.8–1.9)g
RR 1.2 (0.7–1.8)h
HR 1.6 (1.1–2.5)i
RR 1.7 (1.0–2.8)j
Development of future dementia. Figure shows the risk of future dementia in diabetic (DM) versus non_diabetic (No DM) patients, as well as the pooled estimate. Test for heterogeneity: chi square=4.02, df=4 (p=0.40), I 2=0.6%
Six studies specifically assessed the risk of developing dementia due to Alzheimer's disease and/or vascular disease [57–59, 64, 66, 67]. All consistently reported that participants with diabetes had a higher risk of both varieties of dementia than non-diabetic participants, with risks ranging from 1.2 to 2.3 for Alzheimer's disease and 2.2 to 3.4 for vascular dementia.
This systematic overview of prospective studies supports the conclusion that, compared to people without diabetes, people with diabetes have: (1) a greater rate of decline in cognitive function; (2) a 1.5-fold greater risk of cognitive decline; and (3) a 1.6-fold greater risk of future dementia. Interestingly, the included studies reported a similar degree of cognitive decline, despite differences in analytic approaches and cognitive assessment tools. Furthermore, these studies probably underestimated the impact of diabetes on cognitive function because they generally excluded cognitively impaired individuals at baseline, and may therefore have 'selected for' healthier individuals with lower risk of cognitive decline. Another factor suggesting that the reports underestimated the effect of diabetes on cognitive decline is the fact that most of the studies did not include information on people who died or who were lost to follow-up, when follow-up success itself could well be linked to good cognitive function. Indeed, in one study, which did report diabetes status of individuals lost to follow-up, diabetic participants had a higher mortality and/or lower follow-up rates than those without diabetes .
These findings are supported by previous reviews of the available longitudinal studies [3, 4, 6]. They are also supported by the large Framingham study  and the Adult Health Study . In the Framingham Study, 2,123 subjects aged 55 to 88 completed a neuropsychological test battery during either the 14th or 15th biennial examination. People with diabetes status were more likely to achieve scores below the 25th percentile on most tests than were non-diabetic individuals. The Adult Health Study followed a cohort of atomic bomb survivors from Hiroshima and Nagasaki. After 34 to 39 years of follow-up, 1,774 participants were screened for dementia. Compared to non-diabetic individuals, diabetes increased the risk of vascular dementia and Alzheimer's dementia 1.3 and 4.4-fold, respectively. These two studies were excluded from this review because they did not report baseline cognitive measurements.
A number of possibilities may explain the association between diabetes and cognitive decline.
First, diabetes is well established as a risk factor for cerebrovascular disease; it is also associated with hypertension and dyslipidaemia. Thus, a relationship between cognitive change and diabetes may be mediated through cerebrovascular disease. This may be more pronounced in the older age group and requires careful consideration when assessing patients.
Second, depression occurs more frequently in people with diabetes  and is difficult to differentiate clinically from dementia and early cognitive decline [74–77]. However, at least one of the studies  reported an association between diabetes and cognitive decline even after adjustment for depression.
Third, hypoglycaemia may affect cognitive function. However, in contrast to the acute negative effect of hypoglycaemia on cognition, there is little evidence to support chronic cognitive impairment secondary to hypoglycaemia. Indeed, intensive treatment regimens that were associated with increased hypoglycaemic episodes in individuals with type 1 diabetes did not adversely affect cognition .
Fourth, hyperglycaemia may also contribute to chronic cognitive impairment. Post mortem studies of senile plaques from the brains of people with Alzheimer dementia found metabolic oxidation products associated with hyperglycaemia [79, 80]. Experimental studies in animal models and in humans without diabetes have shown that poor glucose regulation after a glucose challenge test was associated with poorer performance on a variety of cognitive tests, the effect being more pronounced in the older age group . Moreover, two of the studies included in this review reported that participants with impaired fasting glucose or impaired glucose tolerance experience more cognitive decline than participants without, further supporting a link between cognitive decline and hyperglycaemia [51, 69, 70]. Finally, prospective epidemiological studies also show a relationship between cognitive decline and clinical markers associated with hyperglycaemia, e.g. use of glucose-lowering medication, diabetes duration and diabetes complications [46, 48, 49, 54, 56, 64].
The overview presented in this study is limited by several factors. It is possible, for example, that studies that did not show an association between diabetes status and cognitive decline may not have been published as often as studies that did. However, many of the studies analysed by us were prospective cohort studies, which examined many risk factors for cognitive decline, and not just diabetes. This makes it unlikely that a lack of an association with diabetes would lead to non-publication. Another limiting factor is that many of the studies analysed used the MMSE/3MS as a measure of cognitive function. This instrument (which was designed as a tool for assessing global cognitive function) has a limited ability to detect changes in specific cognitive domains such as attention and processing speed [17, 82]. As these domains may be selectively impaired in people with diabetes the MMSE/3MS will underestimate the impact of diabetes on cognitive function . This possibility is supported by the fact that the overall estimated effect of the MMSE/3MS was smaller than the overall estimate obtained from studies that used the DSS.
The study is also limited by the differences in the studies included with respect to: (1) the definition of a clinically meaningful decline in cognitive function; (2) identification of people with and without diabetes; (3) age groups that were studied; (4) cognitive assessment tools employed; (5) degree of statistical adjustment for confounders; (6) degree of cognitive impairment permitted in studied participants at baseline; and (7) completeness of follow-up that ranged from 73 to 92%. Despite these differences, only two studies reported that diabetes non-significantly reduced the risk for cognitive decline. In one study, this finding was only noted in young participants, while findings in older participants were consistent with the results from the other studies . In the other study, this finding was only noted for women, and only in certain cognitive tests. The large confidence interval and wide variability of scores between tests reported in this study suggest that a larger sample size could possibly have altered the results . The consistency of our results, despite the differences in the studies, highlights the robustness of the conclusion that diabetes is indeed a risk factor for cognitive decline.
Despite this relationship, there is no evidence to date that diabetes management affects the rate or nature of cognitive dysfunction. Indeed, a recent review of the effect of therapy concluded that no studies were appropriate for inclusion in meta analysis . Nevertheless, the results of the prospective studies summarised here suggest that cognitive dysfunction should be considered as yet another chronic consequence and disabling manifestation of diabetes. They highlight the importance of including measurements of cognitive function in future studies of glucose-lowering and other therapies in people with diabetes, to determine whether or not this decline can be mitigated.
Areosa Sastre A, Grimley Evans J (2005) Effect of the treatment of Type II diabetes mellitus on the development of cognitive impairment and dementia. The Cochrane Library, Issue 2,http://www.cochrane.org/cochrane/revabstr/AB003804.htm
Lobo A, Launer LJ, Fratiglioni L et al (2000) Prevalence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic diseases in the elderly research group. Neurology 54(Suppl 5):S4–S9PubMed
Morris MC, Evans DA, Hebert LE, Bienias JL (1999) Methodological issues in the study of cognitive decline. Am J Epidemiol 149:789–793PubMed
Colsher PL, Wallace RB (1991) Epidemiologic considerations in studies of cognitive function in the elderly: methodology and nondementing acquired dysfunction. Epidemiol Rev 13:1–27PubMed
Teng EL, Chui HC (1987) The Modified Mini-Mental State (3MS) examination. J Clin Psychiatr 48:314–318
Tombaugh TN, McIntyre NJ (1992) The mini-mental state examination: a comprehensive review. J Am Geriatr Soc 40:922–935PubMed
Brayne C, Spiegelhalter DJ, Dufouil C et al (1999) Estimating the true extent of cognitive decline in the old. J Am Geriatr Soc 47:1283–1288PubMed
Wechsler D (1981) The Wechsler Adult Intelligence Scale-Revised. The Psychological Corporation, New York
Desmond DW, Moroney JT, Sano M, Stern Y (1996) Recovery of cognitive function after stroke. Stroke 27:1798–1803PubMed
Dik MG, Deeg DJ, Bouter LM, Corder EH, Kok A, Jonker C (2000) Stroke and apolipoprotein E epsilon4 are independent risk factors for cognitive decline: a population-based study. Stroke 31:2431–2436PubMed
Henon H, Durieu I, Guerouaou D, Lebert F, Pasquier F, Leys D (2001) Poststroke dementia: incidence and relationship to prestroke cognitive decline. Neurology 57:1216–1222PubMed
Kalmijn S, Feskens EJ, Launer LJ, Kromhout D (1996) Cerebrovascular disease, the apolipoprotein e4 allele, and cognitive decline in a community-based study of elderly men. Stroke 27:2230–2235PubMed
Meneilly GS, Cheung E, Tessier D, Yakura C, Tuokko H (1993) The effect of improved glycemic control on cognitive functions in the elderly patient with diabetes. J Gerontol 48:M117–M121PubMed
Feskens EJ, Havekes LM, Kalmijn S, de KP, Launer LJ, Kromhout D (1994) Apolipoprotein e4 allele and cognitive decline in elderly men. BMJ 309:1202–1206PubMed
Grodstein F, Chen J, Pollen DA et al (2000) Postmenopausal hormone therapy and cognitive function in healthy older women. J Am Geriatr Soc 48:746–752PubMed
Kalmijn S, Launer LJ, Lindemans J, Bots ML, Hofman A, Breteler MM (1999) Total homocysteine and cognitive decline in a community-based sample of elderly subjects: the Rotterdam Study. Am J Epidemiol 150:283–289PubMed
Launer LJ, Feskens EJ, Kalmijn S, Kromhout D (1996) Smoking, drinking, and thinking. The Zutphen Elderly Study. Am J Epidemiol 143:219–227PubMed
Szklo M, Cerhan J, Diez-Roux AV et al (1996) Estrogen replacement therapy and cognitive functioning in the Atherosclerosis Risk in Communities (ARIC) Study. Am J Epidemiol 144:1048–1057PubMed
Yaffe K, Cauley J, Sands L, Browner W (1997) Apolipoprotein E phenotype and cognitive decline in a prospective study of elderly community women. Arch Neurol 54:1110–1114PubMed
Yaffe K, Grady D, Pressman A, Cummings S (1998) Serum estrogen levels, cognitive performance, and risk of cognitive decline in older community women. J Am Geriatr Soc 46:816–821PubMed
Yaffe K, Browner W, Cauley J, Launer L, Harris T (1999) Association between bone mineral density and cognitive decline in older women. J Am Geriatr Soc 47:1176–1182PubMed
Tzourio C, Dufouil C, Ducimetiere P, Alperovitch A (1999) Cognitive decline in individuals with high blood pressure: a longitudinal study in the elderly. EVA Study Group. Epidemiology of Vascular Aging. Neurology 53:1948–1952PubMed
Nguyen HT, Black SA, Ray LA, Espino DV, Markides KS (2002) Predictors of decline in MMSE scores among older Mexican Americans. J Gerontol A Biol Sci Med Sci 57:M181–M185PubMed
Tilvis RS, Kahonen-Vare MH, Jolkkonen J, Valvanne J, Pitkala KH, Strandberg TE (2004) Predictors of cognitive decline and mortality of aged people over a 10-year period. J Gerontol A Biol Sci Med Sci 59:268–274PubMed
Ott A, Stolk RP, van HF, Pols HA, Hofman A, Breteler MM (1999) Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 53:1937–1942PubMed
Yoshitake T, Kiyohara Y, Kato I et al (1995) Incidence and risk factors of vascular dementia and Alzheimer's disease in a defined elderly Japanese population: the Hisayama Study. Neurology 45:1161–1168PubMed
Leibson CL, Rocca WA, Hanson VA et al (1997) Risk of dementia among persons with diabetes mellitus: a population-based cohort study. Am J Epidemiol 145:301–308PubMed
Knopman D, Boland LL, Mosley T et al (2001) Cardiovascular risk factors and cognitive decline in middle-aged adults. Neurology 56:42–48PubMed
Yaffe K, Blackwell T, Kanaya AM, Davidowitz BA, Barrett-Connor E, Krueger K (2004) Diabetes, impaired fasting glucose, and development of cognitive impairment in older women. Neurology 63:658–663PubMed
Comijs HC, van TT, Geerlings SW et al (2004) Do severity and duration of depressive symptoms predict cognitive decline in older persons? Results of the Longitudinal Aging Study Amsterdam. Aging Clin Exp Res 16:226–232PubMed
Paterniti S, Verdier-Taillefer MH, Dufouil C, Alperovitch A (2002) Depressive symptoms and cognitive decline in elderly people. Longitudinal study. Br J Psychiatr 181:406–410CrossRef
Vlassara H, Bucala R, Striker L (1994) Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest 70:138–151PubMed